Predict your next investment

Corporation
HEALTHCARE | Biotechnology
scmlifescience.com

See what CB Insights has to offer

Founded Year

2014

Stage

IPO | IPO

Total Raised

$58.23M

Date of IPO

6/17/2020

About SCM Lifescience

SCM Lifescience (KOSDAQ: 298060) develops treatment options for difficult to treat diseases using proprietary stem cell isolation technology and stem cell production technology. SCM Lifescience aims to contribute to the advancement of the stem cell sector through its various business areas including high-purity stem cell storage, large-volume culture of stem cell for investigative purposes, and stem cell research.

SCM Lifescience Headquarter Location

Jungsuk Building A Bdlg, Room 310 366, Seohae-daero, Jung-gu

Incheon, 22332,

South Korea

+82 (032)881-3600

Latest SCM Lifescience News

SCM Lifescience to in-license iPSCs-based diabetes drug from U.S. firm2021.07.02 13:23

Jul 2, 2021

SCM Lifescience to in-license iPSCs-based diabetes drug from U.S. firm 2021.07.02 13:23:46 | 2021.07.02 13:24:15 Receiver SCM Lifescience has agreed to in-license a diabetes drug using pancreatic beta cells derived from induced pluripotent stem cells (iPSCs) from San Diego-based Allele Biotechnology and Pharmaceuticals, the South Korean stem cell therapy developer announced on Thursday. The deal value is $750,000 based on the upfront payment and could go up to $3 million depending on future development milestones. Under the agreement, SCM Lifescience will have the exclusive right to the development, regulatory approval, production and sales of Allele’s diabetes therapy in Korea. The two companies announced a joint research and development agreement over the pipeline in 2019. Since iPSCs can be derived from adult human tissue cells, they not only bypass the need for embryos or other ethically charged cells but can be customized in a patient-matched manner, meaning that each individual could have their own pluripotent stem cell line for treatment purposes. With the agreement, SCM Lifescience will be able to expand its pipeline to include iPSC-based therapies. The Korean company has conducted R&D activities focusing on adult stem cells. Last week, SCM Lifescience made an equity investment into Vita Therapeutics, a U.S. biotech firm developing an iPSCs-based therapy to treat hereditary rare diseases that affect the muscular system. SCM Lifescience said iPSC-based diabetes therapies could replace insulin injections that are painful and inconvenient due to higher dosing frequency. By Park Yoon-gyun and Minu Kim FRI

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing SCM Lifescience

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

SCM Lifescience is included in 3 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharmaceuticals

14,138 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

SCM Lifescience Patents

SCM Lifescience has filed 6 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Biotechnology
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/24/2017

8/24/2021

Clusters of differentiation, Immunology, Immune system, Transcription factors, Human cells

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

2/24/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

8/24/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Clusters of differentiation, Immunology, Immune system, Transcription factors, Human cells

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.